Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewUK 14,304 is a full α2 adrenergic agonist. Centrally active following systemic administration in vivo.
Water-soluble Salt also available.
UK 14,304 is also offered as part of the Tocriscreen FDA-Approved Drugs. Find out more about compound libraries available from Tocris.
M. Wt | 292.14 |
Formula | C11H10BrN5 |
Storage | Store at RT |
CAS Number | 59803-98-4 |
PubChem ID | 2435 |
InChI Key | XYLJNLCSTIOKRM-UHFFFAOYSA-N |
Smiles | BrC1=C(NC2=NCCN2)C=CC2=NC=CN=C12 |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solvent | Max Conc. mg/mL | Max Conc. mM | |
---|---|---|---|
Solubility | |||
DMSO | 100 |
The following data is based on the product molecular weight 292.14. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 3.42 mL | 17.12 mL | 34.23 mL |
5 mM | 0.68 mL | 3.42 mL | 6.85 mL |
10 mM | 0.34 mL | 1.71 mL | 3.42 mL |
50 mM | 0.07 mL | 0.34 mL | 0.68 mL |
References are publications that support the biological activity of the product.
Andorn et al (1988) Specific [3H]UK-14,304 binding in human cortex occurs at multiple high affinity states with α2-adrenergic selectivity and different affinities for GTP. Life Sci. 43 1805 PMID: 2904634
Chopin et al (1999) Effects of alpha-2 adrenoceptor agonists and antagonists on circling behavior in rats with unilateral 6-hydroxyDA lesions of the nigrostriatal pathway. J.Pharmacol.Exp.Ther. 288 798 PMID: 9918591
Macdonald et al (1997) Gene targeting - homing in on α2-adrenoceptor-subtype function. TiPS 18 211 PMID: 9227000
If you know of a relevant reference for UK 14,304, please let us know.
Keywords: UK 14,304, UK 14,304 supplier, α2-adrenoceptor, alpha2-adrenoceptors, a2-adrenoceptors, agonists, α2-Adrenergic, alpha2-Adrenergic, a2-adrenergic, Receptors, UK14304, Adrenergic, Alpha-2, 0425, Tocris Bioscience
Citations are publications that use Tocris products. Selected citations for UK 14,304 include:
Tunstall et al (2011) MT2 receptors mediate the inhibitory effects of melatonin on nitric oxide-induced relaxation of porcine isolated coronary arteries. J Neurosci 336 127 PMID: 20959363
Akoume et al (2019) A Differential Hypofunctionality of Gαi Proteins Occurs in Adolescent Idiopathic Scoliosis and Correlates with the Risk of Disease Progression. Sci Rep 9 10074 PMID: 31296888
Sadeghi et al (2015) μ-Opioid receptor activation and noradrenaline transport inhibition by tapen. in rat single locus coeruleus neurons. J Pharmacol Exp Ther 172 460 PMID: 24372103
Jasmin et al (2002) The NK1 receptor mediates both the hyperalgesia and the resistance to mor. in mice lacking noradrenaline. Proc Natl Acad Sci U S A 99 1029 PMID: 11805341
Do you know of a great paper that uses UK 14,304 from Tocris? Please let us know.
There are currently no reviews for this product. Be the first to review UK 14,304 and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.